We thank the editor for allowing us to clarify an aspect of our recent article ([@B1]) in response to Liu et al. ([@B2]). We and others ([@B3]) found that KsJ mice resist excessive weight gain on a high-fat (HF) diet. There are well-known strain differences in this response. Nevertheless, epididymal fat pad mass and fed plasma nonesterified fatty acid levels were increased by HF in both genotypes (Table 1 in ref. [@B1]). We did not claim obesity or diabetes. We agree that β-cell dysfunction was subclinical by basic measures after 12 weeks' exposure (Table 1 in ref. [@B1]).

Importantly, insulin secretion was reduced in HF-fed KsJ mice when they were challenged with glucose in vivo 15--120 min (Fig. 2*A* vs. 2*B* in ref. [@B1]). Our original submission showed the control and HF-diet data within each genotype together, but the figure was modified in review. While insulin area under the curve was similar over the whole glucose challenge (Fig. 2*C* in ref. [@B1]), it was significantly lower in the second phase (15--120 min: KsJ HF diet, 155.4 ± 24.52 vs. KsJ control diet, 239.4 ± 20.60; *P* \< 0.05, *n* = 6). In vitro insulin secretion from islets of HF-fed KsJ mice showed a trend for suppressed glucose-stimulated insulin secretion (Fig. 3*E* in ref. [@B1]). There were fewer islets in the HF-fed KsJ mice due to β-cell loss (which follows failure) (Fig. 3*A*--*C* in ref. [@B1]), and we chose size-matched islets to better compare the secretory profile with our transgenics. Thus, Fig. 3*E* in ref. [@B1] effectively overestimates the secretory capacity of HF-fed KsJ mice by selecting their "healthy" surviving islets. Overall we concluded that there was β-cell failure in HF-fed KsJ mice.

The positive message is that β-cell--specific 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) overexpression unexpectedly augments glucose-stimulated insulin secretion against a lipotoxic challenge. Modest β-cell 11β-HSD1 elevation resembled the pattern found in mice that robustly compensate on HF diet. Going over this optimal threshold (homozygotes) compromised β-cell function, as found in genetically diabetic mice. As much as we would prefer simplistic linear answers to our research questions, the data are compatible with a U-shaped response.

Liu et al. ([@B2]) are incorrect in their assertion that glucocorticoids are purely suppressive of β-cell function---we provided a list of published data that evidenced both positive and negative effects. We offered plausible explanations for the discrepancies.
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